J.B. Chemicals & Pharmaceuticals FY26: Torrent’s Inheritance, Margin Smoke, and the CDMO Hangover

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

J.B. Chemicals ended FY26 in the care of new parent Torrent Pharmaceuticals (48.8% stake as of Mar’26), following a takeover completed in Jan–Feb’26. Revenue fell 5% YoY to ₹904 cr in Q4—the first quarter under Torrent management—but the company described this quarter as “operational reset”: distribution network optimisation, discontinuation of low-margin trade generics, and alignment of sales practices with the parent. Operating margins benefited materially: gross margin rose to 70% from 66% YoY, and adjusted EBITDA margin expanded 200 bps to 27%.

The tailwind masks a structural shift. Torrent has deliberately exited the trade generics business (~7–8% of prior India revenue), a margin-dilutive segment that makes reported growth look worse than the underlying branded business (+8% in Q4, +11% in FY26). Net profit collapsed 23% to ₹101 cr in Q4 after one-off charges, but adjusted profit sits at ₹150 cr.

The cloud: CDMO revenue remained flat at ₹445 cr in FY26, a business Torrent expects to grow. Management flagged execution speed as the constraint—product development resourcing is the bottleneck, not demand.

A balance sheet with ₹1,200 cr net cash. A merger with Torrent awaiting regulatory sign-off (hearing scheduled for June). And a company in transition.

2. Introduction

Established in 1976 as J.B. Mody Chemicals and Pharmaceuticals Ltd, the company has spent the last 50 years stitching together a diversified pharmaceutical portfolio across domestic formulations, international markets, and contract manufacturing. By March 2025, before the acquisition, it ranked 22nd in the Indian Pharmaceutical Market (as per IQVIA MAT Mar’26) with six brands exceeding ₹100 cr annual sales.

In June–July 2025, Torrent Pharmaceuticals Ltd. initiated a takeover, acquiring 46.39% from Tau Investment Holdings Pte Ltd (a KKR affiliate) at an equity value of ~₹25,689 cr on a fully diluted basis. The deal closed in Jan–Feb 2026; Torrent’s stake rose to 48.8% by March. Simultaneously, Torrent Pharma took board control and management control.

Management changes arrived in rapid succession: Aman Mehta appointed MD on Jan 21, 2026 (replacing Nikhil Chopra, who exited as CEO in Mar’26); CFO Kaushal Singh Solanki appointed Feb 5, replacing Narayan Saraf. In March 2026, three senior executives resigned (Kunal Khanna, Dilip Singh Rathore, Jason D’souza), reflecting the churn of new ownership.

CRISIL upgraded the long-term credit rating to AA+/Stable in March 2026, removing it from “watch developing” status. The upgrade cited the acquisition completion, Torrent’s support articulation, and improved credit profile.

A shareholder meeting in April 2026 approved an amalgamation scheme with Torrent—shareholders will receive 51 Torrent shares for every 100 JB shares held. The NCLT hearing was scheduled for the second week of June.

3. Business Model: WTF Do They Even Do?

JB Chemicals operates three core engines: domestic formulations, international business, and contract development and manufacturing operations (CDMO).

Domestic Formulations (~60% of FY26 revenue, ₹2,461 cr) is a diversified chronic and acute therapy portfolio. The company ranks 22nd in IPM with strength in cardiology and gastroenterology—therapies where Torrent parent also has established brands. The field force spans ~2,500 medical representatives engaging ~345,000 healthcare professionals. Six mega-brands exceed ₹100 cr in annual sales. In FY26, the domestic business grew 9% (branded business +11%), outpacing IPM growth of 10%.

International Formulations (~23% of FY26, ₹1,154 cr) covers regulated and semi-regulated markets. The company is among the top-five global manufacturers of medicated and herbal lozenges. Geographic footprint includes 40+ countries across North America, Europe, Asia, Africa, Latin America, Russia–CIS, and the Gulf. Generics exports flow to USA, UK, Australia, Canada, and South Africa; branded generics to Africa, Southeast Asia, the Gulf, and Latin America. FY26 saw 2% growth, depressed by logistics constraints (container shortages to Middle East and Asia) and Torrent-led credit policy harmonisation.

CDMO Business (~11% of FY26, ₹445 cr) serves global over-the-counter manufacturers: Innova, Kenvue, P&G, Reckitt—the top-five OTC companies by management’s account. The company supplies lozenges, tablets, and capsules in multiple dosage forms. FY26 revenue was flat YoY; growth drivers include new contract execution and customer wallet-share expansion. Management flagged slow product development resourcing as the execution bottleneck.

Manufacturing footprint: 8 facilities across Ankleshwar, Panoli, and Daman (Gujarat and union territory). 40+ global regulatory accreditations (US FDA, EU GMP, WHO GMP, TGA Australia, ANVISA Brazil). Dosage forms: tablets, capsules, lozenges, radio-diagnostics, APIs.

R&D spend: ₹57.7 cr in FY26 on differentiated formulations, fixed-dose combinations, and controlled/modified-release products. Recent approval: Cilnidipine + Bisoprolol combination.

Notable: Novartis Trademark License Agreement (Dec 2023). The company licensed an ophthalmology portfolio from Novartis for the India market, effective January 2027. Upfront consideration: USD 116 mn (to be paid by Dec 31, 2026). Exclusive promotion and distribution agreement with Novartis Healthcare: ₹125 cr. This marks entry into ophthalmology—a 3-year distribution window.

4. Financials Overview

Figures are consolidated, in ₹ crore. Result type: Quarterly (latest Q4 FY26, Mar 31, 2026).

Full Year FY26:

• Revenue: ₹4,148 cr (+5.9% YoY)
• EBITDA: ₹1,107 cr (+7.3%)
• PAT: ₹709 cr (+7.4%)
• EPS: ₹44.19 (+4.3%)

Q4 Narrative (from May 2026 Concall):

Management characterised Q4 as an “operational reset” that “temporarily impacted performance.” Integration actions explicitly cited as one-off/transitionary:

• Discontinuation of low-margin trade generics in